标题
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
作者
关键词
-
出版物
Cell Death & Disease
Volume 6, Issue 6, Pages e1794-e1794
出版商
Springer Nature
发表日期
2015-06-18
DOI
10.1038/cddis.2015.143
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
- (2014) B. Tessoulin et al. BLOOD
- Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
- (2014) Patricia A.J. Muller et al. CANCER CELL
- Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
- (2014) Bo Hong et al. CURRENT DRUG TARGETS
- PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
- (2014) Patricia Izetti et al. INVESTIGATIONAL NEW DRUGS
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
- (2014) C R R Rocha et al. Cell Death & Disease
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
- (2013) Ziyad Binkhathlan et al. CURRENT CANCER DRUG TARGETS
- PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
- (2013) Manujendra N. Saha et al. MOLECULAR CANCER THERAPEUTICS
- Role of Glutathione in Cancer Progression and Chemoresistance
- (2013) Nicola Traverso et al. Oxidative Medicine and Cellular Longevity
- APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
- (2013) X Peng et al. Cell Death & Disease
- Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies
- (2012) S. Murray et al. CANCER TREATMENT REVIEWS
- P53 and its molecular basis to chemoresistance in breast cancer
- (2012) Stian Knappskog et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo
- (2011) Wenjie Bao et al. CELL CYCLE
- Quaternary structure of the specific p53–DNA complex reveals the mechanism of p53 mutant dominance
- (2011) Ricardo Aramayo et al. NUCLEIC ACIDS RESEARCH
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
- (2010) Joel L. Kaar et al. PROTEIN SCIENCE
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
- (2009) J M R Lambert et al. ONCOGENE
- Clinical Outcomes and Correlates of TP53 Mutations and Cancer
- (2009) A. I. Robles et al. Cold Spring Harbor Perspectives in Biology
- PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
- (2008) J Shen et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started